Clinical Trial Update: Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing avalglucosidase alfa to alglucosidase alfa in late-onset Pompe disease patients who have not been treated before, with completed results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Drugs mentioned

• Alglucosidase alfa (alglucosidase alfa)
• Avalglucosidase alfa (avalglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II;Pompe's Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-04-08